Register Login

Karyopharm Therapeutics Inc (KPTI)

(10% Negative) Karyopharm Therapeutics Inc (KPTI) Announces Delay in care Trials for myelofibrosis expected in March Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 8:52 p.m.

    📋 Karyopharm Therapeutics Inc (KPTI) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 07:04:08

    Event Type: Clinical Trial Update

    Event Details:

    Karyopharm Therapeutics Inc (KPTI) Announces Clinical Trial Update Karyopharm Therapeutics Inc (KPTI) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: care, trial
    • Diseases/Conditions: myelofibrosis expected in March, regulatory filings
    • Clinical Stage: Phase 3
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: Top-Line Data
    • Updated Timeline: fourth quarter and full year 2025
      • expected in March. Positive data from our SENTRY trial could unlock our opportunity to improve patient outcomes and redefine the standard-of-care in myelofibrosis. Our teams are actively preparing for regulatory filings, commercialization and the opportunity to rapidly launch with the first ever combination therapy in a multi-billion dollar market,” said Richard Paulson, President and Chief Executive Officer of Karyopharm. “In endometrial cancer, we remain focused and on track to report top-line data from our Phase 3 XPORT-EC-042 trial in mid-2026
      • expected in March 2026
      • targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995

    🔬 Clinical Development Pipeline (Karyopharm Therapeutics Inc):

    Product Type Development Stage Therapeutic Area Source
    Selinexor 60 MG DRUG Phase PHASE2 Multiple Myeloma ClinicalTrials.gov
    Physician's Choice Treatment OTHER Phase PHASE2 Myelofibrosis ClinicalTrials.gov
    Standard-of-Care OTHER Phase PHASE1 Diabetic Foot Ulcers ClinicalTrials.gov
    Selinexor DRUG Phase PHASE1 Advanced Urothelial Carcinoma ClinicalTrials.gov
    Pembrolizumab BIOLOGICAL Phase PHASE1 Advanced Urothelial Carcinoma ClinicalTrials.gov
    KPT-9274 DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    methotrexate/hydrocortisone/cytarabine DRUG Phase PHASE1 Acute Leukemia of Ambiguous Lineage in Relapse ClinicalTrials.gov
    Methotrexate DRUG Phase PHASE1 Acute Leukemia of Ambiguous Lineage in Relapse ClinicalTrials.gov
    Filgrastim BIOLOGICAL Phase PHASE1 Acute Leukemia of Ambiguous Lineage in Relapse ClinicalTrials.gov
    Fludarabine DRUG Phase PHASE1 Acute Leukemia of Ambiguous Lineage in Relapse ClinicalTrials.gov
    Cytarabine DRUG Phase PHASE1 Acute Leukemia of Ambiguous Lineage in Relapse ClinicalTrials.gov
    Venetoclax DRUG Phase PHASE1 Acute Leukemia of Ambiguous Lineage in Relapse ClinicalTrials.gov
    VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection) BIOLOGICAL Phase PHASE1 Head and Neck Cancers- Squamous Cell ClinicalTrials.gov
    Pembrolizumab (KEYTRUDA®) DRUG Phase PHASE1 Head and Neck Cancers- Squamous Cell ClinicalTrials.gov
    VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection) BIOLOGICAL Phase PHASE1 Head and Neck Cancers- Squamous Cell ClinicalTrials.gov
    G-CSF DRUG Phase PHASE2 Lymphoma ClinicalTrials.gov
    Etoposide DRUG Phase PHASE2 Lymphoma ClinicalTrials.gov
    Cyclophosphamide DRUG Phase PHASE2 Lymphoma ClinicalTrials.gov
    Mesna DRUG Phase PHASE2 Lymphoma ClinicalTrials.gov
    Cisplatin DRUG Phase PHASE2 Lymphoma ClinicalTrials.gov
    Dexamethasone DRUG Phase PHASE2 Lymphoma ClinicalTrials.gov
    Gemcitabine DRUG Phase PHASE2 Lymphoma ClinicalTrials.gov
    Rituximab DRUG Phase PHASE2 Lymphoma ClinicalTrials.gov
    Ibrutinib DRUG Phase PHASE2 Lymphoma ClinicalTrials.gov
    Mezigdomide DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Belantamab Mafodotin DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Clarithromycin DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Elotuzumab DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Ixazomib DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Carfilzomib DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Daratumumab DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Bortezomib DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Pomalidomide DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Lenalidomide DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Matching Placebo for selinexor DRUG Phase PHASE3 Endometrial Cancer ClinicalTrials.gov
    Dexamethasone Oral DRUG Phase PHASE3 Multiple Myeloma ClinicalTrials.gov
    KPT-330 DRUG Phase PHASE1 Relapsed Acute Lymphoblastic Leukemia (ALL) ClinicalTrials.gov
    Placebo matching for Selinexor (continuous therapy) DRUG Phase PHASE2 Relapsed/Refractory Diffuse Large B-cell Lymphoma ClinicalTrials.gov
    Selinexor (continuous therapy) DRUG Phase PHASE2 Relapsed/Refractory Diffuse Large B-cell Lymphoma ClinicalTrials.gov
    Cisplatin (combination therapy) DRUG Phase PHASE2 Relapsed/Refractory Diffuse Large B-cell Lymphoma ClinicalTrials.gov
    Dexamethasone (combination therapy) DRUG Phase PHASE2 Relapsed/Refractory Diffuse Large B-cell Lymphoma ClinicalTrials.gov
    Gemcitabine (combination therapy) DRUG Phase PHASE2 Relapsed/Refractory Diffuse Large B-cell Lymphoma ClinicalTrials.gov
    Rituximab (combination therapy) DRUG Phase PHASE2 Relapsed/Refractory Diffuse Large B-cell Lymphoma ClinicalTrials.gov
    Placebo matching for Selinexor (combination therapy) DRUG Phase PHASE2 Relapsed/Refractory Diffuse Large B-cell Lymphoma ClinicalTrials.gov
    Selinexor (combination therapy) DRUG Phase PHASE2 Relapsed/Refractory Diffuse Large B-cell Lymphoma ClinicalTrials.gov
    Oxaliplatin DRUG Phase PHASE1 Relapsed or Refractory Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Tafasitamab DRUG Phase PHASE1 Relapsed or Refractory Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Polatuzumab Vedotin DRUG Phase PHASE1 Relapsed or Refractory Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Bendamustine DRUG Phase PHASE1 Relapsed or Refractory Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Ruxolitinib DRUG Phase PHASE3 Myelofibrosis ClinicalTrials.gov
    Placebo OTHER Phase PHASE3 Myelofibrosis ClinicalTrials.gov
    Pharmacological Study OTHER Phase PHASE2 Recurrent Small Cell Lung Carcinoma ClinicalTrials.gov
    Laboratory Biomarker Analysis OTHER Phase PHASE2 Recurrent Small Cell Lung Carcinoma ClinicalTrials.gov
    Docetaxel DRUG Phase PHASE1 Recurrent Squamous Cell Lung Carcinoma ClinicalTrials.gov
    dose-escalated selinexor treatment DRUG Phase PHASE1 Rectal Neoplasms ClinicalTrials.gov
    standard dose capecitabine DRUG Phase PHASE1 Rectal Neoplasms ClinicalTrials.gov
    standard dose pelvic radiation therapy RADIATION Phase PHASE1 Rectal Neoplasms ClinicalTrials.gov
    decitabine DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Bone marrow biopsy PROCEDURE Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Cladribine DRUG Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Sorafenib DRUG Phase PHASE1 Leukemia ClinicalTrials.gov
    Idarubicin DRUG Phase PHASE2 Acute Myeloid Leukemia (Relapsed/Refractory) ClinicalTrials.gov
    Doxorubicin DRUG Phase PHASE1 Soft Tissue Sarcoma ClinicalTrials.gov
    Irinotecan DRUG Phase PHASE1 Solid Tumor Malignancy ClinicalTrials.gov
    Elotuzumab, Selinexor, and Dexamethasone (ESd) DRUG Phase PHASE2 Relapsed Multiple Myeloma ClinicalTrials.gov
    selinexor (KPT-330) DRUG Phase PHASE2 Myelodysplastic Syndromes ClinicalTrials.gov
    Ifosfamide DRUG Phase PHASE1 Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Carboplatin DRUG Phase PHASE1 Diffuse Large B-Cell Lymphoma ClinicalTrials.gov
    Folinic Acid DRUG Phase PHASE1 Colorectal Neoplasm ClinicalTrials.gov
    5-FU DRUG Phase PHASE1 Colorectal Neoplasm ClinicalTrials.gov
    Open Label Selinexor DRUG Phase PHASE2 Thymoma ClinicalTrials.gov
    Verdinexor DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Liposomal doxorubicin DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Placebo (for selinexor) DRUG Phase PHASE2 Multiple Myeloma ClinicalTrials.gov
    Acetaminophen DRUG Phase PHASE1 Solid Tumor ClinicalTrials.gov
    Ara-C DRUG Phase PHASE2 Acute Myeloid Leukemia (AML) ClinicalTrials.gov
    Hydroxyurea DRUG Phase PHASE2 Acute Myeloid Leukemia (AML) ClinicalTrials.gov
    Vehicle Gel OTHER Phase PHASE1 Diabetic Foot Ulcers ClinicalTrials.gov
    Atezolizumab DRUG Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov
    Bevacizumab DRUG Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov
    Selinexor Pill DRUG Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov
    Fosaprepitant DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Autologous Hematopoietic Cell Transplantation (HCT) PROCEDURE Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Melphalan DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    Correlative studies OTHER Phase PHASE1 Recurrent Melanoma ClinicalTrials.gov
    Daunorubicin DRUG Phase PHASE1 Leukemia ClinicalTrials.gov
    mitoxantrone hydrochloride DRUG Phase PHASE1 Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities ClinicalTrials.gov
    Methylprednisolone DRUG Phase PHASE1 Refractory Multiple Myeloma ClinicalTrials.gov
    Tipiracil DRUG Phase PHASE2 Metastatic Colorectal Cancer ClinicalTrials.gov
    Trifluridine DRUG Phase PHASE2 Metastatic Colorectal Cancer ClinicalTrials.gov
    Paclitaxel DRUG Phase PHASE2 Ovarian Cancer ClinicalTrials.gov
    KCP-330 DRUG Phase PHASE1 Sarcoma ClinicalTrials.gov
    Nivolumab DRUG Phase PHASE1 Solid Tumors ClinicalTrials.gov
    Niacin ER DRUG Phase PHASE1 Solid Tumors ClinicalTrials.gov
    Selinexor 100 MG DRUG Phase PHASE2 Multiple Myeloma ClinicalTrials.gov
    Selinexor 80 MG DRUG Phase PHASE2 Multiple Myeloma ClinicalTrials.gov
    ASTX727 DRUG Phase PHASE1 Relapsed/Refractory Multiple Myeloma (RRMM) ClinicalTrials.gov
    KPT-8602 DRUG Phase PHASE1 Relapsed/Refractory Multiple Myeloma (RRMM) ClinicalTrials.gov
    Momelotinib DRUG Phase PHASE2 Myelofibrosis ClinicalTrials.gov
    Pacritinib DRUG Phase PHASE2 Myelofibrosis ClinicalTrials.gov
    Selinexor 40 mg DRUG Phase PHASE2 Myelofibrosis ClinicalTrials.gov
    Carmustine DRUG Phase PHASE1 Glioblastoma Multiforme ClinicalTrials.gov
    TTField DEVICE Phase PHASE1 Glioblastoma Multiforme ClinicalTrials.gov
    Standard Fractionated Radiation therapy (RT) RADIATION Phase PHASE1 Glioblastoma Multiforme ClinicalTrials.gov
    Lomustine (CCNU) DRUG Phase PHASE1 Glioblastoma Multiforme ClinicalTrials.gov
    Temozolomide (TMZ) DRUG Phase PHASE1 Glioblastoma Multiforme ClinicalTrials.gov
    Biospecimen Collection PROCEDURE Phase PHASE1 Relapsed Myelodysplastic Syndrome ClinicalTrials.gov
    Bone Marrow Aspiration and Biopsy PROCEDURE Phase PHASE1 Relapsed Myelodysplastic Syndrome ClinicalTrials.gov
    Eltanexor DRUG Phase PHASE1 Relapsed Myelodysplastic Syndrome ClinicalTrials.gov
    Lenalidomide capsule DRUG Phase PHASE2 Multiple Myeloma ClinicalTrials.gov
    Bortezomib Injection DRUG Phase PHASE2 Multiple Myeloma ClinicalTrials.gov
    Selinexor 20 MG Oral Tablet DRUG Phase PHASE2 Multiple Myeloma ClinicalTrials.gov
    FOLFIRI DRUG Phase PHASE1 Non-Small Cell Lung Carcinoma (NSCLC) ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Karyopharm Therapeutics Inc
    • Ticker Symbol: KPTI

Search

News categories